SI9300423A - Peg-interferon conjugates - Google Patents
Peg-interferon conjugates Download PDFInfo
- Publication number
- SI9300423A SI9300423A SI9300423A SI9300423A SI9300423A SI 9300423 A SI9300423 A SI 9300423A SI 9300423 A SI9300423 A SI 9300423A SI 9300423 A SI9300423 A SI 9300423A SI 9300423 A SI9300423 A SI 9300423A
- Authority
- SI
- Slovenia
- Prior art keywords
- interferon
- conjugate
- conjugates
- peg
- lower alkyl
- Prior art date
Links
- 229940079322 interferon Drugs 0.000 title claims abstract description 93
- 102000014150 Interferons Human genes 0.000 claims abstract description 83
- 108010050904 Interferons Proteins 0.000 claims abstract description 83
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 56
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 150000002334 glycols Chemical class 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000003277 amino group Chemical group 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 43
- -1 poly (oxy-1,2-ethanediyl Chemical group 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YBDQLHBVNXARAU-UHFFFAOYSA-N 2-methyloxane Chemical compound CC1CCCCO1 YBDQLHBVNXARAU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- AFFYTLSODCIHIH-UHFFFAOYSA-N bis(3-methylpyridin-2-yl) carbonate Chemical compound CC1=CC=CN=C1OC(=O)OC1=NC=CC=C1C AFFYTLSODCIHIH-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical class ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/935,770 US5382657A (en) | 1992-08-26 | 1992-08-26 | Peg-interferon conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SI9300423A true SI9300423A (en) | 1994-03-31 |
Family
ID=25467637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9300423A SI9300423A (en) | 1992-08-26 | 1993-08-06 | Peg-interferon conjugates |
Country Status (37)
Country | Link |
---|---|
US (1) | US5382657A (zh) |
EP (1) | EP0593868B1 (zh) |
JP (1) | JP2859105B2 (zh) |
KR (1) | KR100295520B1 (zh) |
CN (3) | CN1183112C (zh) |
AT (1) | ATE165102T1 (zh) |
AU (1) | AU668742B2 (zh) |
BG (1) | BG98067A (zh) |
BR (1) | BR9303469A (zh) |
CA (1) | CA2103829C (zh) |
CZ (1) | CZ169393A3 (zh) |
DE (1) | DE69317979T2 (zh) |
DK (1) | DK0593868T3 (zh) |
EE (1) | EE9400151A (zh) |
ES (1) | ES2116376T3 (zh) |
FI (1) | FI109765B (zh) |
HR (1) | HRP931094A2 (zh) |
HU (1) | HUT67013A (zh) |
IL (1) | IL106750A0 (zh) |
IS (1) | IS4067A (zh) |
LT (1) | LT3174B (zh) |
LV (1) | LV10907B (zh) |
MW (1) | MW7693A1 (zh) |
MX (1) | MX9305146A (zh) |
MY (1) | MY131445A (zh) |
NO (1) | NO933028D0 (zh) |
NZ (2) | NZ248452A (zh) |
OA (1) | OA09850A (zh) |
PH (1) | PH30460A (zh) |
PL (1) | PL300194A1 (zh) |
RO (1) | RO112730B1 (zh) |
SI (1) | SI9300423A (zh) |
SK (1) | SK89893A3 (zh) |
UY (1) | UY23635A1 (zh) |
YU (1) | YU56693A (zh) |
ZA (1) | ZA936098B (zh) |
ZW (1) | ZW11193A1 (zh) |
Families Citing this family (288)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE135370T1 (de) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
DE59010941D1 (de) | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
DK0730470T3 (da) * | 1993-11-10 | 2002-06-03 | Enzon Inc | Forbedrede interferonpolymerkonjugater |
AU1916295A (en) * | 1994-02-08 | 1995-08-29 | Amgen, Inc. | Oral delivery of chemically modified proteins |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
DE4435087A1 (de) * | 1994-09-30 | 1996-04-04 | Deutsches Krebsforsch | Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
DE19514087A1 (de) * | 1995-04-13 | 1996-10-17 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
CA2236591C (en) | 1995-11-02 | 2012-01-03 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
BR9812466A (pt) * | 1997-09-18 | 2000-09-19 | Hoffmann La Roche | Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica |
CA2312975C (en) | 1997-12-17 | 2012-08-21 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
FR2774687B1 (fr) * | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
TWI243057B (en) * | 1998-03-26 | 2005-11-11 | Schering Corp | Formulations for protection of peg-interferon alpha conjugates |
US6180096B1 (en) | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
JP4574007B2 (ja) * | 1998-04-28 | 2010-11-04 | メルク・セローノ・ソシエテ・アノニム | ポリオール−ifn−ベータ複体 |
CZ300540B6 (cs) | 1998-05-15 | 2009-06-10 | Schering Corporation | Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1 |
ITMI981148A1 (it) * | 1998-05-22 | 1999-11-22 | Therapicon Srl | Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie |
CA2330611A1 (en) * | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
PL192364B1 (pl) * | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
US6593459B1 (en) * | 1998-06-16 | 2003-07-15 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
US20030143662A1 (en) * | 1998-06-16 | 2003-07-31 | Cummings Richard D. | Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof |
US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
BR9915548A (pt) * | 1998-10-16 | 2001-08-14 | Biogen Inc | Proteìnas de fusão de interferon-beta e usos |
DE69930015T2 (de) | 1998-10-16 | 2006-10-12 | Biogen Idec Ma Inc., Cambridge | Polymerkonjugate von interferon-beta-1a und deren verwendungen |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
BR122013003013B8 (pt) | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
ATE246202T1 (de) * | 1999-01-29 | 2003-08-15 | Hoffmann La Roche | Gcsf konjugate |
US6923966B2 (en) | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
US6362162B1 (en) | 1999-04-08 | 2002-03-26 | Schering Corporation | CML Therapy |
US6605273B2 (en) | 1999-04-08 | 2003-08-12 | Schering Corporation | Renal cell carcinoma treatment |
CN1390132A (zh) | 1999-04-08 | 2003-01-08 | 先灵公司 | 聚乙二醇化干扰素α在黑素瘤治疗中的应用 |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
AU6069800A (en) | 1999-07-07 | 2001-01-30 | Zymogenetics Inc. | Human cytokine receptor |
WO2001005819A1 (en) * | 1999-07-15 | 2001-01-25 | Kuhnil Pharm. Co., Ltd. | Novel water soluble-cyclosporine conjugated compounds |
US7431921B2 (en) * | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
WO2001026677A1 (fr) | 1999-10-12 | 2001-04-19 | Santen Pharmaceutical Co., Ltd. | Complexe a base d'interferon et son utilisation en medecine |
CN1309423C (zh) | 1999-11-12 | 2007-04-11 | 马克西根控股公司 | 干扰素γ偶联物 |
SK8292002A3 (en) * | 1999-11-12 | 2002-12-03 | Maxygen Holdings Ltd | A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof |
WO2001035978A1 (en) | 1999-11-19 | 2001-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted bifunctional molecules and therapies based thereon |
US6887842B1 (en) * | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
EP1234035B1 (en) | 1999-12-03 | 2010-02-24 | ZymoGenetics, Inc. | Human cytokine receptor |
ES2327606T3 (es) | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | Conjugados de g-csf. |
EP1908477A3 (en) * | 2000-01-24 | 2008-06-11 | Schering Corporation | Combination of temozolomide and pegylated interferon-alpha for treating cancer |
MXPA02007172A (es) * | 2000-01-24 | 2002-12-13 | Schering Corp | Combinacion de temozolomida y alfa interferon pegilado para tratamiento de cancer. |
DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
KR100353392B1 (ko) * | 2000-03-13 | 2002-09-18 | 선바이오(주) | 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법 |
US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
JP5170931B2 (ja) * | 2000-10-16 | 2013-03-27 | 中外製薬株式会社 | Peg修飾エリスロポエチン |
US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
ES2329012T3 (es) | 2000-11-07 | 2009-11-20 | Zymogenetics, Inc. | Receptor del factor de necrosis tumoral humano. |
AU2002251988A1 (en) * | 2001-02-20 | 2002-09-04 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Bcma及びtaciの両者を結合する抗体 |
ATE432288T1 (de) | 2001-02-27 | 2009-06-15 | Maxygen Aps | Neue interferon-beta-ähnliche moleküle |
WO2002070655A2 (en) | 2001-03-02 | 2002-09-12 | Zymogenetics, Inc. | Mouse cytokine receptor |
US7038015B2 (en) * | 2001-04-06 | 2006-05-02 | Maxygen Holdings, Ltd. | Interferon gamma polypeptide variants |
US6958388B2 (en) | 2001-04-06 | 2005-10-25 | Maxygen, Aps | Interferon gamma polypeptide variants |
WO2002083166A1 (fr) * | 2001-04-10 | 2002-10-24 | Santen Pharmaceutical Co., Ltd. | Complexes de polymeres d'interferons et leur utilisation medicinale |
DK2116259T3 (da) | 2001-05-24 | 2012-05-21 | Zymogenetics Inc | TACI-immunoglobulinfusionsproteiner |
JP4142569B2 (ja) * | 2001-06-22 | 2008-09-03 | 協和醗酵工業株式会社 | 軟膏剤 |
MD2053C2 (ro) * | 2001-07-10 | 2003-07-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Remediu cu acţiune interferonogenă |
ATE376020T1 (de) | 2001-08-22 | 2007-11-15 | Bioartificial Gel Technologies Inc | Verfahren zu herstellung von aktivierten polyethylenglykolen |
EP1461067A1 (en) * | 2001-12-07 | 2004-09-29 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
KR100888371B1 (ko) | 2002-01-17 | 2009-03-13 | 동아제약주식회사 | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 |
WO2003061577A2 (en) * | 2002-01-18 | 2003-07-31 | Biogen Idec Ma Inc. | Polyalkylene glycol with moiety for conjugating biologically active compound |
AU2003221291A1 (en) * | 2002-03-13 | 2003-09-22 | Beijing Jiankai Technology Co., Ltd. | Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
EP1496925A4 (en) * | 2002-04-11 | 2007-05-30 | Zymogenetics Inc | USE OF INTERLEUKIN-24 FOR THE TREATMENT OF OVARIAL CARCINOMA |
EP1497415B1 (en) | 2002-04-19 | 2010-12-29 | ZymoGenetics, L.L.C. | Methods for detection or modulation of the interaction of a cytokine receptor with its ligand |
CN1671420A (zh) | 2002-06-21 | 2005-09-21 | 诺和诺德医疗保健公司 | Peg化因子ⅶ糖型 |
CA2491178A1 (en) * | 2002-07-03 | 2004-01-15 | Maxygen Holdings Ltd. | Full-length interferon gamma polypeptide variants |
WO2004012773A1 (en) * | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
KR20050083677A (ko) * | 2002-09-05 | 2005-08-26 | 더 제너럴 하스피탈 코포레이션 | 변형 아시알로 인터페론 및 그의 용도 |
WO2004021991A2 (en) * | 2002-09-05 | 2004-03-18 | The General Hospital Corporation | Asialo-interferons and the treatment of liver cancer |
AU2003285286A1 (en) * | 2002-09-27 | 2004-04-19 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol) |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
RS20050501A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
RS20050502A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of interferon- beta with enhanced biological potency |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
WO2004074345A2 (en) * | 2003-02-19 | 2004-09-02 | Pharmacia Corporation | Carbonate esters of polyethylene glycol activated by means of oxalate esters |
CN1997666A (zh) * | 2003-02-26 | 2007-07-11 | 印特缪恩股份有限公司 | 聚乙二醇修饰的干扰素组合物及其使用方法 |
WO2004078127A2 (en) * | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Continuous delivery methods for treating hepatitis virus infection |
CA2458085A1 (en) | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US7157559B2 (en) | 2003-08-07 | 2007-01-02 | Zymogenetics, Inc. | Homogeneous preparations of IL-28 and IL-29 |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
EP2263684A1 (en) | 2003-10-10 | 2010-12-22 | Novo Nordisk A/S | IL-21 derivatives |
EP2407470A3 (en) | 2003-10-14 | 2015-06-10 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
EP2633866A3 (en) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
WO2005042563A2 (en) * | 2003-10-22 | 2005-05-12 | Akzo Nobel N.V. | Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
WO2005062949A2 (en) * | 2003-12-23 | 2005-07-14 | Intermune, Inc. | Method for treating hepatitis virus infection |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
GB2429207A (en) | 2004-02-02 | 2007-02-21 | Ambrx Inc | Modified human interferon polypeptides and their uses |
AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
MXPA06013412A (es) * | 2004-05-19 | 2007-01-23 | Maxygen Inc | Polipeptidos de interferon-alfa y conjugados. |
WO2005123113A2 (en) * | 2004-06-14 | 2005-12-29 | Intermune, Inc. | Interferon compositions and methods of use thereof |
KR101699142B1 (ko) * | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
EP1771573A4 (en) * | 2004-07-21 | 2009-02-18 | Ambrx Inc | BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS |
EP2389944A1 (en) | 2004-07-29 | 2011-11-30 | ZymoGenetics, L.L.C. | Use of IL-28 and IL-29 to treat cancer |
DE602005022895D1 (de) | 2004-08-12 | 2010-09-23 | Schering Corp | Stabile pegylierte interferon-formulierung |
EP2301963A1 (en) | 2004-09-23 | 2011-03-30 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
EP1836298B1 (en) * | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
WO2006086396A2 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
EP1891107B1 (en) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
CA2607651A1 (en) * | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
ATE529442T1 (de) * | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
CA2611836A1 (en) * | 2005-06-13 | 2006-12-21 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
JP2008546708A (ja) | 2005-06-17 | 2008-12-25 | ノバルティス アクチエンゲゼルシャフト | Hcvにおけるサングリフェリンの使用 |
US7695710B2 (en) | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
CA2612901A1 (en) * | 2005-06-20 | 2007-01-04 | Pepgen Corporation | Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau |
CA2613737C (en) * | 2005-06-29 | 2017-05-23 | Yeda Research And Development Co. Ltd. | Recombinant interferon .alpha.2 (ifn.alpha.2) mutants |
BRPI0613962A2 (pt) | 2005-07-25 | 2009-03-24 | Intermune Inc | inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c |
AU2005335491B2 (en) * | 2005-08-18 | 2010-11-25 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
PL1931697T3 (pl) | 2005-09-28 | 2011-03-31 | Zymogenetics Inc | Antagoniści interleukiny IL-17A i IL-17F oraz sposoby ich zastosowania |
GEP20104956B (en) | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
AU2006304856A1 (en) * | 2005-10-21 | 2007-04-26 | Synageva Biopharma Corp. | Glycolated and glycosylated poultry derived therapeutic proteins |
DE602006020480D1 (de) * | 2005-11-08 | 2011-04-14 | Ambrx Inc | Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide |
PT2339014E (pt) * | 2005-11-16 | 2015-10-13 | Ambrx Inc | Métodos e composições compreendendo aminoácidos não-naturais |
EP1968635B1 (en) * | 2005-12-14 | 2014-09-17 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
AU2007205545B9 (en) | 2006-01-12 | 2012-10-18 | Hokusan Co. Ltd. | Oral composition containing interferon-alpha |
CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
CA2643680A1 (en) | 2006-04-11 | 2007-11-22 | Novartis Ag | Hcv/hiv inhibitors and their uses |
JP5313129B2 (ja) * | 2006-05-02 | 2013-10-09 | アロザイン, インコーポレイテッド | 非天然アミノ酸置換ポリペプチド |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
EP2029738A2 (en) | 2006-05-24 | 2009-03-04 | Novo Nordisk Health Care AG | Factor ix analogues having prolonged in vivo half life |
JP5031827B2 (ja) | 2006-06-01 | 2012-09-26 | 程云 | 予防或いは肝損傷を治療するペプチッド |
CN1911447B (zh) * | 2006-06-30 | 2010-05-12 | 复旦大学 | 转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途 |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
JP2010510171A (ja) * | 2006-08-21 | 2010-04-02 | ユナイテッド セラピューティクス コーポレーション | ウイルス感染症の治療のための併用療法 |
WO2008030613A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Hybrid suppressor trna for vertebrate cells |
WO2008030614A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
DK2615108T3 (en) | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
CN103965347B (zh) * | 2007-05-02 | 2017-07-18 | Ambrx公司 | 经修饰干扰素β多肽和其用途 |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
US8597634B2 (en) * | 2007-09-04 | 2013-12-03 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof |
PT2186830E (pt) * | 2007-09-04 | 2012-06-20 | Biosteed Gene Expression Tech Co Ltd | Interferão alfa 2b modificado com polietilenoglicol e método de preparação e aplicações do mesmo |
CA2697992C (en) | 2007-10-04 | 2017-08-22 | Zymogenetics, Inc. | B7 family member zb7h6 and related compositions and methods |
US8216571B2 (en) | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
AU2008326324B9 (en) | 2007-11-20 | 2012-11-15 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
HUE036548T2 (hu) | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | IL-31-re specifikus humanizált antitest molekulák |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
BRPI0822530B1 (pt) | 2008-04-03 | 2022-03-22 | Biosteed Gene Expression Tech. Co., Ltd | Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição |
PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
EP2623112B1 (en) | 2008-06-27 | 2015-03-04 | Zymogenetics, Inc. | Soluble hybrid Fc gamma receptors and related methods |
UA118536C2 (uk) * | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування |
EP3216800A1 (en) * | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
MX348657B (es) | 2008-09-26 | 2017-06-21 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
EP3025727A1 (en) | 2008-10-02 | 2016-06-01 | The J. David Gladstone Institutes | Methods of treating liver disease |
CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
ES2537566T3 (es) | 2009-06-04 | 2015-06-09 | Novartis Ag | Métodos para identificación de sitios para conjugación de IgG |
WO2011014882A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
CN102753573A (zh) | 2009-12-21 | 2012-10-24 | Ambrx公司 | 经过修饰的牛促生长素多肽和其用途 |
NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
EP2569331A1 (en) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptide inhibitors of vla4 |
US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
CN103180339B (zh) | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
WO2011159930A2 (en) | 2010-06-16 | 2011-12-22 | Medtronic, Inc. | Damping systems for stabilizing medications in drug delivery devices |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
IN2012MN02896A (zh) | 2010-06-24 | 2015-06-12 | Panmed Ltd | |
RU2586296C2 (ru) | 2010-07-23 | 2016-06-10 | Демеркс, Инк. | Композиции норибогаина |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
BR112013003522B1 (pt) | 2010-08-17 | 2021-05-25 | Ambrx, Inc. | polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
KR20140035305A (ko) | 2010-10-05 | 2014-03-21 | 노파르티스 아게 | C형 간염 바이러스 감염의 새로운 치료법 |
US9011833B2 (en) | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
RU2013129824A (ru) | 2010-11-30 | 2015-01-10 | Новартис Аг | Новое лечение инфекции вируса гепатита с |
EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
BR112013025021A2 (pt) | 2011-03-31 | 2017-03-01 | Novartis Ag | alisporivir para tratar infecções por vírus de hepatite c. |
PT2694087E (pt) | 2011-04-01 | 2015-04-09 | Novartis Ag | Tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas |
BR112013025934A2 (pt) | 2011-04-13 | 2016-09-06 | Debiopharm Int Sa | tratamento de infecção pelo vírus da hepatite c com alisporivir |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
US9422338B2 (en) | 2011-05-19 | 2016-08-23 | Epodose Llc | Compounds that bind to the erythropoietin receptor |
BR112014000055A2 (pt) | 2011-07-01 | 2017-06-13 | Bayer Ip Gmbh | polipeptídeos de fusão de relaxina e usos dos mesmos |
WO2013011113A1 (en) | 2011-07-20 | 2013-01-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for determining treatment response in patients infected with hcv genotype 4 |
CA2846092A1 (en) * | 2011-08-25 | 2013-02-28 | Nanogen Pharmaceutical Biotechnology | Peg-interferon lambda 1 conjugates |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
US20140228281A1 (en) | 2011-09-27 | 2014-08-14 | Novartis Ag | Alisporivr for treatment of hepatitis c virus infection |
JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
SG11201402899TA (en) | 2011-12-06 | 2014-07-30 | Univ Leland Stanford Junior | Methods and compositions for treating viral diseases |
EP2788003A4 (en) | 2011-12-09 | 2015-05-27 | Demerx Inc | PHOSPHATESTER OF NORIBOGAIN |
EP2807168A4 (en) | 2012-01-25 | 2015-10-14 | Demerx Inc | SYNTHETIC VOACANGINE |
US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法 |
CN104411332B (zh) | 2012-03-30 | 2018-11-23 | 索伦托治疗有限公司 | 与vegfr2结合的全人抗体 |
WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
WO2013174988A1 (en) | 2012-05-24 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects |
KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
CA2877573A1 (en) | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
EP2864358B1 (en) | 2012-06-22 | 2019-08-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
BR112015004022B1 (pt) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | Aminoácidos modificados compreendendo um grupo azido |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
CA2896133A1 (en) | 2012-12-20 | 2014-06-26 | Demerx, Inc. | Substituted noribogaine |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
CA2913977C (en) | 2013-05-31 | 2022-11-29 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
DK3137078T3 (da) | 2014-05-01 | 2019-06-11 | Eiger Biopharmaceuticals Inc | Behandling af hepatitis delta-virusinfektion |
US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
AU2015301753B2 (en) | 2014-08-12 | 2021-04-08 | Massachusetts Institute Of Technology | Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein |
WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
CN107148282A (zh) | 2014-08-22 | 2017-09-08 | 索伦托治疗有限公司 | 结合cxcr3的抗原结合蛋白 |
US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
EA037151B1 (ru) * | 2014-11-06 | 2021-02-11 | Фармаэссентия Корпорейшн | Способ лечения с использованием пегилированного интерферона |
CN107532146A (zh) * | 2015-03-17 | 2018-01-02 | 国立大学法人信州大学 | 通过使用ifn的非贴壁培养制备树突状细胞的方法 |
KR102514971B1 (ko) | 2015-04-21 | 2023-03-27 | 아이거 바이오파마슈티컬스 인코포레이티드 | 로나파르닙 및 리토나버를 포함하는 약제 조성물 |
MX2018005230A (es) | 2015-11-03 | 2018-08-15 | Hoffmann La Roche | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. |
JP7187315B2 (ja) | 2015-11-04 | 2022-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | デルタ型肝炎ウイルス感染の処置 |
US10118963B2 (en) | 2016-01-29 | 2018-11-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
WO2018087345A1 (en) | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON |
US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
WO2018132516A1 (en) | 2017-01-10 | 2018-07-19 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator |
US20190374611A1 (en) | 2017-01-18 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
CN110637027A (zh) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
WO2019020593A1 (en) | 2017-07-25 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS |
US11446365B2 (en) | 2017-08-09 | 2022-09-20 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
US20220056093A1 (en) | 2018-09-11 | 2022-02-24 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
CN112771071A (zh) | 2018-09-28 | 2021-05-07 | 麻省理工学院 | 胶原蛋白定位的免疫调节分子及其方法 |
EP3867265A1 (en) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
EP3914289A1 (en) | 2019-01-23 | 2021-12-01 | Massachusetts Institute of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
BR112021015832A2 (pt) | 2019-02-12 | 2022-01-18 | Ambrx Inc | Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos |
MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
WO2021178612A1 (en) | 2020-03-05 | 2021-09-10 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
KR20220151202A (ko) | 2020-03-11 | 2022-11-14 | 암브룩스, 인코포레이티드 | 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법 |
WO2021228983A1 (en) | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer |
EP3912627B1 (en) | 2020-05-20 | 2022-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of coronavirus infections |
CA3185614A1 (en) | 2020-06-22 | 2021-12-30 | Janssen Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis d virus infection |
JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲート、その方法及び使用 |
WO2022043496A2 (en) | 2020-08-28 | 2022-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of mait cells as biomarkers and biotargets in covid-19 |
WO2022079205A1 (en) | 2020-10-15 | 2022-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ifn-alpha polypeptides for the treatment of coronavirus infections |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2651657A (en) * | 1949-05-21 | 1953-09-08 | Standard Oil Dev Co | Synthetic lubricating oil |
SE337223B (zh) * | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
US3619371A (en) * | 1967-07-03 | 1971-11-09 | Nat Res Dev | Production of a polymeric matrix having a biologically active substance bound thereto |
SE343210B (zh) * | 1967-12-20 | 1972-03-06 | Pharmacia Ab | |
DK132327A (zh) * | 1968-07-16 | |||
US3632828A (en) * | 1968-12-16 | 1972-01-04 | Dow Chemical Co | Polyethylene glycol monomethyl ether carbonates |
BE758425A (fr) * | 1969-12-02 | 1971-04-16 | Baxter Laboratories Inc | Streptokinase liee chimiquement a une matrice en carbohydrate ( |
DE2247163A1 (de) * | 1972-09-26 | 1974-03-28 | Merck Patent Gmbh | Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
US4094744A (en) * | 1976-11-18 | 1978-06-13 | W. R. Grace & Co. | Water-dispersible protein/polyurethane reaction product |
US4275000A (en) * | 1977-08-22 | 1981-06-23 | National Research Development Corporation | Peptide macromolecular complexes |
JPS55110105A (en) * | 1979-02-19 | 1980-08-25 | Japan Atom Energy Res Inst | Preparation of polymer composition containing physiologically active material |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
US4486344A (en) * | 1983-03-28 | 1984-12-04 | Miles Laboratories, Inc. | Urea-linked immunogens, antibodies, and preparative method |
JPS6098988A (ja) * | 1983-11-01 | 1985-06-01 | Chemo Sero Therapeut Res Inst | Lpf−haの精製法 |
JPS60127952A (ja) | 1983-12-14 | 1985-07-08 | Fanuc Ltd | 領域加工方法 |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0154316B1 (en) * | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
WO1987000056A1 (en) * | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
US5100664A (en) * | 1985-09-20 | 1992-03-31 | Cetus Corporation | Human IL-2 as a vaccine adjuvant |
US4818769A (en) * | 1985-09-20 | 1989-04-04 | Cetus Corporation | Method of controlling stress-related disease in livestock by administration of human IL-2 |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4810638A (en) * | 1986-07-24 | 1989-03-07 | Miles Inc. | Enzyme-labeled antibody reagent with polyalkyleneglycol linking group |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US4851220A (en) * | 1986-11-26 | 1989-07-25 | Schering Corporation | Stable oleaginous gel |
US4871538A (en) * | 1987-07-13 | 1989-10-03 | Schering Corporation | Insoluble copper-alpha interferon complex |
JPS6471490A (en) * | 1987-08-21 | 1989-03-16 | Wellcome Found | Novel complex |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5199360A (en) | 1988-09-27 | 1993-04-06 | Sirkka Koistinen | Table constructions |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
AU4660789A (en) * | 1988-11-23 | 1990-06-12 | Genentech Inc. | Polypeptide derivatives |
US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0470128B2 (en) * | 1989-04-19 | 2003-08-13 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
ES2085297T3 (es) * | 1989-05-27 | 1996-06-01 | Sumitomo Pharma | Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada. |
JP2978187B2 (ja) * | 1989-11-02 | 1999-11-15 | 日本ケミカルリサーチ株式会社 | 修飾スーパーオキサイドディスムターゼの製造法 |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
EP0502962B1 (de) * | 1989-12-01 | 1996-03-13 | BASF Aktiengesellschaft | Hirudin-Muteine und deren Polyalkylenglykolkonjugate |
JPH04202293A (ja) * | 1990-11-29 | 1992-07-23 | Tonen Corp | 作動油 |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
-
1992
- 1992-08-26 US US07/935,770 patent/US5382657A/en not_active Expired - Lifetime
-
1993
- 1993-08-03 HR HR07/935,770A patent/HRP931094A2/hr not_active Application Discontinuation
- 1993-08-06 SI SI9300423A patent/SI9300423A/sl unknown
- 1993-08-11 CA CA002103829A patent/CA2103829C/en not_active Expired - Lifetime
- 1993-08-13 ES ES93112983T patent/ES2116376T3/es not_active Expired - Lifetime
- 1993-08-13 DK DK93112983T patent/DK0593868T3/da active
- 1993-08-13 DE DE69317979T patent/DE69317979T2/de not_active Expired - Lifetime
- 1993-08-13 EP EP93112983A patent/EP0593868B1/en not_active Expired - Lifetime
- 1993-08-13 AT AT93112983T patent/ATE165102T1/de active
- 1993-08-16 MW MW7693A patent/MW7693A1/xx unknown
- 1993-08-18 HU HU9302366A patent/HUT67013A/hu unknown
- 1993-08-18 CZ CZ931693A patent/CZ169393A3/cs unknown
- 1993-08-19 ZA ZA936098A patent/ZA936098B/xx unknown
- 1993-08-20 NZ NZ248452A patent/NZ248452A/en unknown
- 1993-08-20 IL IL106750A patent/IL106750A0/xx unknown
- 1993-08-20 SK SK898-93A patent/SK89893A3/sk unknown
- 1993-08-20 NZ NZ264872A patent/NZ264872A/en unknown
- 1993-08-20 PH PH46719A patent/PH30460A/en unknown
- 1993-08-20 AU AU44780/93A patent/AU668742B2/en not_active Ceased
- 1993-08-23 JP JP5229504A patent/JP2859105B2/ja not_active Expired - Lifetime
- 1993-08-23 BG BG98067A patent/BG98067A/xx unknown
- 1993-08-23 RO RO93-01141A patent/RO112730B1/ro unknown
- 1993-08-24 UY UY23635A patent/UY23635A1/es unknown
- 1993-08-24 MY MYPI93001695A patent/MY131445A/en unknown
- 1993-08-25 NO NO933028A patent/NO933028D0/no unknown
- 1993-08-25 IS IS4067A patent/IS4067A/is unknown
- 1993-08-25 MX MX9305146A patent/MX9305146A/es active IP Right Grant
- 1993-08-25 CN CNB971054339A patent/CN1183112C/zh not_active Expired - Lifetime
- 1993-08-25 KR KR1019930016550A patent/KR100295520B1/ko not_active IP Right Cessation
- 1993-08-25 LV LVP-93-1040A patent/LV10907B/en unknown
- 1993-08-25 YU YU56693A patent/YU56693A/sh unknown
- 1993-08-25 PL PL93300194A patent/PL300194A1/xx unknown
- 1993-08-25 BR BR9303469A patent/BR9303469A/pt not_active Application Discontinuation
- 1993-08-25 CN CN93116479A patent/CN1039015C/zh not_active Expired - Lifetime
- 1993-08-25 LT LTIP888A patent/LT3174B/lt not_active IP Right Cessation
- 1993-08-25 FI FI933740A patent/FI109765B/fi not_active IP Right Cessation
- 1993-08-26 OA OA60405A patent/OA09850A/fr unknown
- 1993-08-26 ZW ZW11193A patent/ZW11193A1/xx unknown
-
1994
- 1994-11-22 EE EE9400151A patent/EE9400151A/xx unknown
-
1997
- 1997-05-23 CN CNB971054347A patent/CN1155618C/zh not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9300423A (en) | Peg-interferon conjugates | |
CA2063886C (en) | Polyethylene protein conjugates | |
KR100254097B1 (ko) | 인터페론결합체 | |
JP5334347B2 (ja) | 化学的に修飾した新規なエリスロポエチン刺激タンパク質組成物および方法 | |
US8372422B2 (en) | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers | |
CZ20003995A3 (en) | Polyol and interferon-beta conjugate | |
AU2002233354B2 (en) | PEG-conjugates of HGT-NK4 | |
AU2002233354A1 (en) | PEG-conjugates of HGT-NK4 | |
US20090185998A1 (en) | New activated poly(ethylene glycols) and related polymers and their applications | |
MXPA05010411A (es) | Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen. | |
US20050281778A1 (en) | Human growth hormone conjugated with biocompatible polymer | |
DE69309452T2 (de) | Herstellung von aktivierten Carbamaten von Polyalkylenglycol und ihre Verwendung | |
KR20040086521A (ko) | 생물학적 활성물질과 생체적합성 고분자의 1:1 접합체,이의 제조방법과 이를 함유하는 약학 조성물 |